PMID- 20664989
OWN - NLM
STAT- MEDLINE
DCOM- 20101123
LR  - 20221207
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 24
IP  - 3
DP  - 2010 Sep
TI  - A phase II study of personalized peptide vaccination combined with gemcitabine 
      for non-resectable pancreatic cancer patients.
PG  - 795-801
AB  - We evaluated the safety of, and clinical and immune responses to personalized 
      peptide vaccination with gemcitabine (GEM) as the first line therapy in patients 
      with non-resectable pancreatic cancer. Pre-vaccination peripheral blood 
      mononuclear cells (PBMCs) and plasma were prepared to examine cellular and 
      humoral responses to 14 and 16 peptides in human leukocyte antigen (HLA)-A24+ or 
      -A2+ patients, respectively. Only the reactive peptides (maximum of 4) were 
      administered weekly at 3 mg/peptide. GEM was administered at 1000 mg/m(2) per 
      week for 3 weeks, followed by 1 week of rest. Twenty-one patients with untreated 
      and non-resectable pancreatic cancer were enrolled. The combination therapy was 
      generally well tolerated. Boosting of cellular and humoral responses to the 
      vaccinated peptides was observed in the post-vaccination (eighth) PBMCs and 
      plasma from 14 of 18 and 13 of 18 patients tested, respectively. The best 
      clinical responses were 7 cases of partial response, 9 cases of stable disease, 
      and 5 cases of progressive disease. Median survival time of all 21 patients was 
      9.0 months (95% CI, 6-15.5 months) with a one year survival rate of 38%. Immune 
      boosting in both cellular and humoral responses was well correlated with overall 
      survival with a hazard ratio of 0.2 (95% CI, 0.06-0.73; log-rank p=0.0239). These 
      results suggest a potential clinical benefit of this combination therapy for 
      non-resectable pancreatic cancer patients as the first line therapy. Further 
      exploration of this approach is warranted.
FAU - Yanagimoto, Hiroaki
AU  - Yanagimoto H
AD  - Department of Surgery, Kansai Medical University, Hirakata, Japan.
FAU - Shiomi, Hisanori
AU  - Shiomi H
FAU - Satoi, Sohei
AU  - Satoi S
FAU - Mine, Takashi
AU  - Mine T
FAU - Toyokawa, Hideyoshi
AU  - Toyokawa H
FAU - Yamamoto, Tomohisa
AU  - Yamamoto T
FAU - Tani, Tohru
AU  - Tani T
FAU - Yamada, Akira
AU  - Yamada A
FAU - Kwon, A-Hon
AU  - Kwon AH
FAU - Komatsu, Nobukazu
AU  - Komatsu N
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Noguchi, Masanori
AU  - Noguchi M
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (Vaccines, Subunit)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimetabolites, Antineoplastic/adverse effects/*therapeutic use
MH  - Cancer Vaccines/adverse effects/*therapeutic use
MH  - Deoxycytidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Female
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunity, Humoral
MH  - Japan
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pancreatic Neoplasms/drug therapy/immunology/mortality/pathology/*therapy
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vaccines, Subunit/therapeutic use
MH  - Gemcitabine
EDAT- 2010/07/29 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/07/29 06:00
PHST- 2010/07/29 06:00 [entrez]
PHST- 2010/07/29 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.3892/or_00000923 [doi]
PST - ppublish
SO  - Oncol Rep. 2010 Sep;24(3):795-801. doi: 10.3892/or_00000923.